Shannon N Westin

early_phase_1phase_1phase_1_2phase_2

Quality-of-Life Assessment

2 trials

phase_1_2phase_2

Pharmacological Study

2 trials

phase_1phase_1_2

Olaparib

2 trials

early_phase_1phase_1

Adavosertib

early_phase_1

Chemotherapy

early_phase_1

Vistusertib

phase_1

Carboplatin

phase_1_2

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

+12 more interventions

20 unique interventions3 categories

Analytics

Trial Phases

Phase 13

Phase 22

Trial Status

Completed1

Other6

Role Distribution

Principal Investigator7

PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT03943173Early Phase 1Active Not Recruiting

BRCA-Mutated Ovarian CarcinomaBRCA1 Gene MutationBRCA2 Gene Mutation+28 more

PrincipalinvestigatorStart date: 2019-06-07

NCT03586661Phase 1Completed

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more

PrincipalinvestigatorStart date: 2019-04-29

NCT02726997Phase 1/2Active Not Recruiting

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Stage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7+12 more

PrincipalinvestigatorStart date: 2016-07-06

NCT02659241Early Phase 1Active Not Recruiting

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Advanced Fallopian Tube CarcinomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal Carcinoma+19 more

PrincipalinvestigatorStart date: 2016-02-04

NCT02208375Phase 1Active Not Recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more

PrincipalinvestigatorStart date: 2014-11-11

NCT04604613Active Not Recruiting

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

PrincipalinvestigatorStart date: 2012-11-08

NCT00788671Phase 2Active Not Recruiting

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Atypical Endometrial HyperplasiaStage I Uterine Corpus Cancer AJCC v7Stage IA Uterine Corpus Cancer AJCC v7+2 more

PrincipalinvestigatorStart date: 2008-11-03

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

High Grade Ovarian Serous Adenocarcinoma3 Primary Peritoneal High Grade Serous Adenocarcinoma3 Endometrial Adenocarcinoma2 Recurrent Fallopian Tube Carcinoma2 Recurrent Ovarian Carcinoma2 Recurrent Primary Peritoneal Carcinoma2 Stage III Fallopian Tube Cancer AJCC v72 Stage III Ovarian Cancer AJCC v6 and v72

Affiliations

M.D. Anderson Cancer Center

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Shannon Westin

M.D. Anderson Cancer Center

High Grade Ovarian Serous AdenocarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+17 more

Shared therapeutic areas:

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)

Similarity Score8%

Sharon Manne

Rutgers Cancer Institute of New Jersey

Stage II Uterine Corpus Cancer AJCC v7Stage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7+15 more

Shared therapeutic areas:

Worked with same sponsors:

Platinum-Resistant Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+13 more

Similarity Score7%

Amir A Jazaeri

M.D. Anderson Cancer Center

7 trials

Shared therapeutic areas:

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)

Similarity Score6%

Lilie L Lin

M.D. Anderson Cancer Center

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+10 more

Shared therapeutic areas:

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)

Similarity Score5%

Emese Zsiros

Roswell Park Cancer Institute

6 trials

Shared therapeutic areas:

Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma+8 more

Worked with same sponsors:

Stage III Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8+4 more

Similarity Score4%

Siqing fu

M.D. Anderson Cancer Center

6 trials

Shared therapeutic areas:

Worked with same sponsors:

M.D. Anderson Cancer CenterNational Cancer Institute (NCI)

Similarity Score3%

Kunle Odunsi

Roswell Park Cancer Institute

Recurrent Ovarian CarcinomaEstrogen Receptor NegativeRecurrent Breast Carcinoma+3 more

Shared therapeutic areas:

Worked with same sponsors:

Recurrent Breast CarcinomaRecurrent Ovarian CarcinomaStage IV Ovarian Cancer AJCC v8+2 more

Roy Strowd, MD

Wake Forest University Health Sciences

7 trials

Shared therapeutic areas:

Worked with same sponsors:

Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+1 more

Vincent Chung

City of Hope Medical Center

9 trials

Shared therapeutic areas:

Worked with same sponsors:

Recurrent Breast CarcinomaRecurrent Ovarian CarcinomaStage III Ovarian Cancer AJCC v8+1 more

A P Chen

National Cancer Institute LAO

8 trials

Shared therapeutic areas:

Worked with same sponsors: